Imaging company IPOs today; Shareholder tries to block Covidien-Medtronic deal;

@FierceMedDev: Boston Scientific wins expanded European approval for Lotus transcatheter valve system. Article | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Placenta plays vital role in fetal development, but much remains in the way of medical breakthroughs and research. More from the NYT | Follow @EmilyWFierce

> Florida-based imaging company iRadimed hopes the IPO that debuted today will pull in $12.6 million towards their non-magnetic infusion pumps. Story

> The FDA is searching for new ways to promote pediatric devices. Story

> A Covidien ($COV) shareholder yesterday filed a class action lawsuit in an attempt to block the company's upcoming takeover by Medtronic ($MDT). Story

Biotech News

@FierceBiotech: ICYMI yesterday: Three more biotechs target $175M in IPO cash amid market tumult. Report | Follow @FierceBiotech

@DamianFierce: A+ photo choice. It's like he's snatching the savings right outta your hand. More from the WSJ | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday, check out the latest issue of FierceBiotech Research. Report | Follow @EmilyMFierce

> Roche is at an Alzheimer's crossroads after mixed data for AC Immune's drug. Story

> 'Economic patriotism' could dampen biopharma's M&A boom. Article

> Cancer vaccine maker immatics adds nearly $30M in Series D. News

> GlaxoSmithKline and Theravance eye Phase III for another COPD contender. Article

> Immunocore and Lilly strike a risk-sharing deal in oncology R&D. News

Pharma News

@FiercePharma: Top-read on FP Tuesday: J&J's powerhouse drug launches drive 21% boost to Q2 pharma sales. Story | Follow @FiercePharma

@EricPFierce: GSK investing $25M in Codexis technology as it looks for 'more elegant' ways to manufacture APIs. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Merck is aiming to revive Zilmax sales, but it's not that easy after safety scare. Article | Follow @CarlyHFierce

> Pfizer amps up its 'Get old' campaign with more content, more social media. Item

> Reuters: Sanofi in $8.5B sell-off talks with Mylan, Abbott, private equity. Report

> Sanofi and others hit hard by India's price caps on heart and diabetes drugs. More

> Ex-China staffers sue GSK for 'illegal' termination amid bribery scandal. Report

Drug Delivery News

> Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve. Item

> UPenn researchers develop nanogel for mitigating lung inflammation. Report

> Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer. More

> Delivering breast cancer drug through the skin grants disease prevention. Article

> Nasal version of naloxone for opioid overdose gets on FDA's fast track. Story

Diagnostics News

> Asuragen gains New York state's OK to launch autism and thyroid tests. More

> Roche and Merck KGaA team on a multicancer companion diagnostic test. Story

> MGC Diagnostics grows international reach with Belgian M&A deal. News

> NeuroVision Imaging's CEO discloses approval timeline for eye test to help spot Alzheimer's. Report

> Maryland researchers expand usefulness of schizophrenia biomarker found in saliva. Article

Pharma Marketing News

> J&J's new hep C med Olysio aced Q2. So why are investors worried? More

> Orphan drug approvals are up, but prices are up more. Report

> Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Story

> In social media, what's easier to grasp--an FDA webinar or an FDA warning letter? More

> Roche's Avastin steps on FDA fast track for new cervical cancer use. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.